It has been clearly established that lipid-lowering treatments such as fibrates can reduce cardiovascular events. Potentially more serious adverse effects, which are more clearly related to drug treatment and are probably dose-dependent, include elevations in hepatic transaminase levels and myopathy; however, these effects are uncommon and generally resolve rapidly when treatment is stopped. The risk of myopathy with fibrate treatment is increased in patients with renal impairment. Clofibrate is associated with an increased risk of gallstones. Lipid-lowering drugs should be administered with extra caution to elderly patients.|
- Drugs Aging 2001;18(9):665-83 -- How well tolerated are lipid-lowering drugs? -- Tomlinson B, Chan P, Lan W.
An interaction with oral anticoagulants was observed.
- Artery 1980;7(1):73-82 -- Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. -- Harvengt C, Heller F, Desager JP.
last update: November 2008
This information is
not intended to be a substitute for professional medical advice. You should not use this material to diagnose or treat a
health condition or disease without consulting with your healthcare provider.
© 1998-2017 Personal Health Zone
Click above for Service Agreement and Contact Information. Accessing this
service binds you to terms stated. Advertisements appear throughout this website as a means of funding the site. This site is updated monthly and operates
independently of any health associations or organizations. The owner of this site has no medical training and the information presented comes from government resources and health professionals in their respected fields.
Home Page: Personal Health Zone